Leukaemic relapses after allogeneic haematopoietic SCT (HSCT) in most instances arise from the original recipient leukaemia clone. Exceptionally, leukaemic relapse can originate from the donor haematopoietic cells.
1
The imide compound thalidomide and its derivative lenalidomide are highly effective against multiple myeloma. Recently, patients receiving prolonged lenalidomide maintenance have been observed to develop secondary cancers including haematological malignancies. [4] [5] [6] We describe the occurrence of donor cell leukaemia in two patients with multiple myeloma, who had undergone allogeneic HSCT, followed by prolonged thalidomide maintenance.
Case 1 was a 57-year-old woman with IgG-l myeloma, who underwent a non-myeloablative HSCT from an HLAmatched brother. Fludarabine (30 mg/m 2 /day Â 3) and TBI (3 Gy in two fractions) were used for conditioning, and CYA and mycophenolate mofetil for GVHD prophylaxis. She engrafted with complete donor chimerism and no GVHD. Thalidomide (100 mg/day, commenced 16 months after HSCT and maintained for 4 years) and bortezomib (1.4 mg Â 16 doses) were administered to control minimal residual myeloma. At 6 years after HSCT, she developed pancytopaenia and an increase in paraprotein. A marrow assessment showed 12% plasma cells and 40% blasts. The blasts were positive for CD10, CD34, CD43, CD79a, PAX5 and terminal deoxynucleotidyltransferase (Tdt), and negative for T-cell and myeloid antigens. Features were consistent with B-cell ALL. Karyotyping showed 43-46, XY, add(3)(p13), add(4)(q33), À8, À9 [cp15], confirming donor origin of the leukaemia. Donor chimerism, as assessed by a quantitative PCR for polymorphic STRs, 7 confirmed full donor chimerism (Figures 1a and b) . To track the probable sequence of leukaemia development, aberrant promoter methylation of CDKN2B, DAPK, ECAD and CDKN1C genes was used as surrogate marker. 8 Aberrant promoter methylation was not found in the myeloma cells at diagnosis (Figure 2 ). Four months after HSCT, however, aberrant CDKN2B methylation was detected. This was followed by DAPK methylation at 15 months, and ECAD and CDKN1C methylation at 78 months when ALL was diagnosed. At morphological remission of the leukaemia, DAPK, ECAD and CDKN1C methylation disappeared, although CDKN2B remained methylated. The subsequent re-emergence of ECAD methylation heralded leukaemic relapse at 90 months, due to which the patient died. The donor had remained well.
Case 2 was a 49-year-old man with IgG-k myeloma, who underwent a non-myeloablative HSCT from an HLAmatched brother. Fludarabine (30 mg/m 2 /day Â 3) and TBI (3 Gy in two fractions) were used for conditioning. He required CYA, azathioprine and thalidomide for control of chronic GVHD. Low-level paraproteinaemia still persisted, so that thalidomide maintenance treatment (100 mg/day) was given. Four years after HSCT, extramedullary osseous plasmacytomas involving the ribs and spine developed, which were treated by radiotherapy (30 Gy). Nine years after HSCT, there was a surge of paraprotein and appearance of circulating blasts. By then, he had received 7 years of thalidomide. Marrow examination showed acute leukaemia. On immunophenotyping, the blasts were positive for CD10, CD19, CD22, CD34, CD38, CD79a, Tdt and myeloperoxidase. The overall features were consistent with acute mixed lineage leukaemia. Karyotyping revealed two clones, one showing 45, XY, À7, and the other 46, XY, del(3)(q25), del(7)(q31q33), del(13)(q22). DNA chimerism analysis showed full donor chimerism, confirming donor origin of the leukaemia (Figure 1c) . He was treated with daunorubicin and Ara-C, and achieved a CR. The donor was healthy but refused to be evaluated.
In both cases, the donor haematopoietic cells had been exposed to various medications. In case 1, there was residual fludarabine from the conditioning regimen, CYA and mycophenolate mofetil for GVHD prophylaxis, and thalidomide and bortezomib for treating residual myeloma. Aberrant CDKN2B methylation first appeared 4 months after HSCT when full donor chimerism was present, followed by DAPK methylation at 15 months. These changes might reflect molecular aberrations in donor haematopoietic cells, with leukaemogenesis pursuant to these early alterations. During the initial phase of marrow repopulation, donor haematopoietic cells are under replicative stress, rendering them particularly sensitive to genotoxic agents. 2, 3 In our case, the early appearance of CDKN2B and DAPK methylation in donor cells could therefore reflect this phenomenon.
In case 2, donor haematopoietic cells were exposed to residual fludarabine, azathioprine for chronic GVHD, and radiotherapy for the plasmacytoma. The presence of deletion of the long arm of chromosome 7 (7q-) and monosomy 7 (À7) in the leukaemic clones strongly suggested therapy-related leukaemia. Fludarabine has been 
Aberrant promoter methylation of a panel of genes as a surrogate marker of the neoplastic clones in case 1. Methylation-specific PCR before HSCT (À1 month) showed that none of the genes was methylated. However, at 4 months after HSCT, aberrant methylation of CDKN2B was already detectable. At 15 months, DAPK methylation also became detectable, albeit weakly. With the development of acute leukaemia (AL), all the four genes could be detected to be methylated. At achievement of CR, only CDKN2B remained methylated. At leukaemic relapse, ECAD methylation re-appeared again.
As there had been no significant change of the myeloma clone size during the clinical history, these aberrant gene methylations probably reflected the leukaemic clone. C, control; M, methylated; PC, plasma cell; U, unmethylated; WCC, white cell count ( Â 10 9 /L). Hb (g/dL); Plt count ( Â 10 9 /L).
linked with therapy-related myelodysplasia and AML (t-MDS/AML), 9 often in conjunction with À7 or 7q-. Prolonged use of azathioprine also leads to t-MDS/AML, 10 which interestingly are also associated with À7 or 7q-. Therefore, the development of donor leukaemia with À7 and 7q-was most likely a result of exposure of donor cells to leukaemogenic agents after HSCT.
In three recent studies of 1533 myeloma patients undergoing lenalidomide maintenance or placebo treatment, 44 cases of second cancers (including 13 cases of haematological malignancies) developed in the patients on lenalidomide (for 42 years) as compared with 11 cases of second cancers in patients on placebo. [4] [5] [6] All of these patients had received previous chemotherapy, including alkylating agents that would strongly predispose to second solid tumours and haematological malignancies. The fact that the secondary cancers included Hodgkin's lymphoma and ALL, 5 which were malignancies hardly observed concomitantly in myeloma patients, makes chance occurrence less likely.
Both thalidomide and lenalidomide belong to the imide group of compounds, which although not oncogenic have potent immunomodulatory effects. The apparent excess of secondary cancers in myeloma patients on prolonged lenalidomide therapy might therefore be related to an immunomodulatory effect that favoured the expansion of cells with genetic mutation(s) due to previous genotoxic agents. A similar mechanism might have operated in our cases, which had prolonged thalidomide maintenance for 4-9 years. The prolonged thalidomide usage, with its protean immunomodulatory functions, might have perturbed the immune system with respect to tumour immunosurveillance, thereby contributing to the subsequent development of leukaemias from the donor haematopoietic cells that had been damaged by genotoxic agents.
